

If you would like to learn more about this study, please contact the study coordinators:

**Northwestern University**

Jonathan Parker  
jtp@northwestern.edu  
Annie Eliopoulos  
annie.elopoulos@nm.org

**Cedars-Sinai Medical Center**

Victoria Amran  
Victoria.Amran@cshs.org

**University of Colorado**

Samantha Hopp  
SAMANTHA.HOPP@CUANSCHUTZ.EDU

**Duke University**

Taylor Hayes  
taylor.hayes@duke.edu

**University of North Carolina**

Melisa Ramirez-Pineda  
melisa\_ramirez-pineda@med.unc.edu



Northwestern University



CEDARS-SINAI

SAMUEL OSCHIN  
CANCER CENTER



University of Colorado  
Anschutz Medical Campus



DUKE UNIVERSITY  
HEALTH SYSTEM



UNC

SCHOOL OF  
MEDICINE



NATIONAL  
CANCER  
INSTITUTE

NWU20-02-01

**Do you have  
endometrial  
intraepithelial  
neoplasia (EIN)/  
complex atypical  
hyperplasia (CAH)?**


**Join**

**A Study on  
Endometrial/Uterine  
Cancer Prevention**



Advances in cancer prevention rely on people at risk for cancer, who participate in them.

Will you join us in the pursuit to prevent cancer?



## Why Is This Study Being Done?

- Patients with EIN have an increased risk of developing uterine/endometrial cancer.
- Better ways to prevent uterine/endometrial cancer are needed.
- This study is designed to look at the impact of megestrol acetate alone, or combined with metformin, on the cells of the uterine lining that lead to the growth of EIN.
- Research suggests that metformin may have anti-cancer properties.
- If successful, this study will help us develop a new option for uterine/endometrial cancer prevention.

## What Are the Study Groups?

- Group 1: Will get a study drug called megestrol acetate. Megestrol acetate is a synthetic version of the human hormone progesterone. It treats breast cancer and endometrial cancer by affecting female hormones involved in cancer growth and is approved by the FDA for treatment of EIN.
- Group 2: Will get two study drugs - megestrol acetate and metformin. Metformin is approved by the FDA for treatment of diabetes, but not for treatment of EIN.



## You may be eligible if you:

- Have EIN/CAH and are planning a hysterectomy
- Are over the age of 18
- Are not currently pregnant or trying to become pregnant

## If you take part in this study, you will be asked to do the following:

- Take one or two pills by mouth twice a day for 3-5 weeks
- Keep a pill diary
- Attend study appointments
- Donate blood samples and complete a physical exam
- Complete your planned hysterectomy

